Although blood‐based synaptic markers are not yet routinely used in CJD diagnostics, previous studies reporting elevated β‐synuclein and increased CSF SNAP‐25 and neurogranin levels support the presence of extensive synaptic damage [38, 39, 40]. This evidence concerns the gene NRGN and Creutzfeldt Jacob disease.